✦ LIBER ✦

383 POSTER A Phase I Study of dasatinib, a Src and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors

✍ Scribed by J. Morgan; G. Demetri; D. Wang; I. MacPherson; P. LoRusso; A. van den Abbeele; V. Brunton; R. Luo; M. Voi; T. Evans

Book ID: 118624011
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 58 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70388-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

383 POSTER A phase 1 study of XL281, a p

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

✍ G.K. Schwartz; S. Yazji; D.S. Mendelson; M.A. Dickson; S.H. Johnston; E.W. Wang; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

358 POSTER A phase I and pharmacokinetic

358 POSTER A phase I and pharmacokinetic (PK) study of CX-3543, a protein-rDNA quadruplex inhibitor, in patients (pts) with advanced solid tumors

✍ A.D. Ricart; K.P. Papadopoulos; D.D. Von Hoff; J.K.C. Lim; R.F. Marschke 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

404 POSTER A phase I study of oral admin

404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

✍ W. Kelly; D. Petrylak; G. Blumenschein; U. Lassen; P. Buhl Jensen; J. DeBono 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

300 POSTER Phase I study of an oral isot

300 POSTER Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors

✍ L.L. Siu; M. Carducci; E.X. Chen; M. Maclean; R. Pili; S. King; T. Patterson; Z. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Phase I Dose-Escalation and Pharmacokine

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

✍ Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.J.; Wang, D.; Morgan, J. A.; Brun 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 238 KB

A phase I, first-in-human dose-escalatio

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB